Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia

NCT06469047 | Not Yet Recruiting

• 1 other identifier: Hanyi20240408
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.

Conditions

AML

Outcome Measures

Primary Outcomes (3)

• N/OFQ

  Serum N/OFQ levels

  24 hours

• IL-1β

  Serum IL-1β levels

  24 hours

• NE

  Serum NE levels

  24 hours

Study Arms (4)

the newly diagnosed group

Diagnostic Test: Enzyme-linked immunosorbent assay

the relapsed group

Diagnostic Test: Enzyme-linked immunosorbent assay

the complete remission group

Diagnostic Test: Enzyme-linked immunosorbent assay

the control group

Diagnostic Test: Enzyme-linked immunosorbent assay

Interventions

Enzyme-linked immunosorbent assay DIAGNOSTIC_TEST

Serum N/OFQ , IL-1β and NE levels were detected.

the complete remission group; the control group; the newly diagnosed group; the relapsed group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients in the Second Hospital of Shanxi Medical University from June 2022 to November 2023

You may qualify if:

• In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ②Leukocyte count ≤ 25×109/L;
• No treatment has been received in the past 6 months.
• None of the candidates are related and known this study, and sign the informed consent.

You may not qualify if:

• Patients who are allergic to the drugs used in this study;
• People with mental illness or cognitive impairment;
• Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.

Sponsors & Collaborators

• Second Hospital of Shanxi Medical University: lead

Study Sites (1)

Second Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China

Location

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: June 16, 2024
• First Posted: June 21, 2024
• Study Start: June 20, 2024
• Primary Completion: November 30, 2024
• Study Completion: December 31, 2024
• Last Updated: June 21, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)